Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Korean Fund Aims For Stem Cell, Gene Therapy Edge

This article was originally published in PharmAsia News

Executive Summary

As some local biosimilar firms such as Celltrion have already got their feet firmly on the ground, the South Korean government is now shifting its strategic focus to support for stem cell and gene therapy ventures to help them advance into a global market where no clear leader has yet emerged.

You may also be interested in...

Korea Launches Inter-agency Body To Stimulate Local R&D, Earmarks $440 Million For Program

SEOUL - The Korean government has set up an inter-ministry team to support local pharmaceutical companies develop globally competitive drugs. The team will offer R&D training for companies looking to diversify their generic pipelines with innovative products as well as some of the start-up cash needed for new R&D programs

Court's Suspended Prison Sentence Brings Disgraced Korean Cloning Researcher A Step Closer To Return To Life Of Science

SEOUL - A Seoul court's two-year suspended prison sentence for disgraced cloning scientist Hwang Woo-Suk appears to be paving the way for a comeback to research in stem cells and human cloning

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts